Investigations and Prosecutions

Most of the major drug companies that sell antipsychotic drugs have paid large civil and/or criminal penalties (or are facing such penalties) for illegally marketing these drugs to doctors and nursing homes as a way to control residents with dementia. This page features national and California news about criminal prosecutions and government imposed penalties on those who are responsible for the misuse of antipsychotic drugs in nursing homes.

Omnicare Accused of Accepting Kickbacks to Promote Anti-Seizure Drug Depakote to Control Nursing Home Residents with Dementia.

Drug Giant AstraZeneca Pays Half-Billion Dollar Penalty for Illegal Marketing of the Antipsychotic Seroquel to Drug Elders with Dementia (April 28, 2010)

U.S. Sues Johnson & Johnson Sued for Illegally Promoting Antipsychotic Drugs for Nursing Home Residents (January 15, 2010)

Omnicare Settles Drug Kickback Cases for $98M (November 3, 2009)

California Attorney General Charges Kern Valley Nursing Home Officials with Using Antipsychotic Drugs as a Deadly Weapon (February 18, 2009)

Eli Lilly Agrees to Pay $1.4 Billion in Criminal and Civil Penalties for Illegally Marketing Zyprexa (January 15, 2009)

U.S. Senator Charles Grassley Seeks Inspector General Investigation on Nursing Home Misuse of Antipsychotic Drugs (December 6, 2007)

Share
Print this page.
Share